Stockscreener 앱 받기
11.62
0.61%
0.07
시간 외 거래:
11.63
0.01
+0.09%
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Price-Driven Insight from (KROS) for Rule-Based Strategy - Stock Traders Daily
Live Keros Therapeutics, Inc. (KROS) Technical Analysis - Traders Union
Keros Therapeutics, Inc. (KROS) Stock Analysis: A Biotech Gem with 74.59% Upside Potential - DirectorsTalk Interviews
Keros Therapeutics, Inc. SEC Filing (Sep 17, 2026) - Stock Titan
(KROS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Bank of New York Mellon Corp Takes $1.11 Million Position in Keros Therapeutics, Inc. $KROS - marketbeat.com
Keros Therapeutics May Offer Up To $350 Million Of SecuritiesSEC Filing - TradingView
Share Buyback Program Approved by Keros Therapeutics (NASDAQ:KROS) Board of Directors - marketbeat.com
Keros Therapeutics (NASDAQ: KROS) Launches $5M Stock Buyback Program Following $20M Milestone from Takeda - Kalkine Media
Keros Therapeutics Announces Share Repurchase Authorization Program - TipRanks
Keros Therapeutics Announces $5 Million Share Repurchase Authorization - The Manila Times
Keros approves $5M buyback after $20M Takeda milestone; cash runway into H2 2028 - TradingView
Keros Therapeutics announces $5M share repurchase program after Takeda payment - TipRanks
Keros Therapeutics, Inc. announces an Equity Buyback for $5 million worth of its shares. - marketscreener.com
Wells Fargo Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $18 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Keros Therapeutics, Inc. authorizes a Buyback Plan. - marketscreener.com
Keros Therapeutics (NASDAQ:KROS) Downgraded by Wall Street Zen to "Strong Sell" - marketbeat.com
Keros Therapeutics (NASDAQ:KROS): Is Its Pipeline Worth the Risk? - Kalkine Media
Empowered Funds LLC Makes New Investment in Keros Therapeutics, Inc. $KROS - marketbeat.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Analysts - marketbeat.com
Understanding the Setup: (KROS) and Scalable Risk - Stock Traders Daily
Keros Therapeutics director Bienaime buys $10,270 in shares By Investing.com - Investing.com South Africa
Keros Therapeutics director Bienaime buys $10,270 in shares - Investing.com
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report? - Yahoo Finance
Man Group plc Purchases Shares of 155,541 Keros Therapeutics, Inc. $KROS - MarketBeat
BlackRock Inc. Buys Shares of 2,794,217 Keros Therapeutics, Inc. $KROS - marketbeat.com
127,885 Shares in Keros Therapeutics, Inc. $KROS Purchased by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Nantahala Capital Management LLC Takes Position in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Upgraded to "Hold" at Zacks Research - marketbeat.com
Keros Therapeutics director Bienaime buys $10,270 of KROS stock By Investing.com - Investing.com India
Keros Therapeutics director Bienaime buys $10,270 of KROS stock - Investing.com
KROS Q2 2026 Earnings: Wider-than-Expected Net Loss Pressures SharesFull Year Guidance - dars.gov.et
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk? - Eastern Progress
Lorena Raquel Lerner Sells 3,568 Shares of Keros Therapeutics (NASDAQ:KROS) Stock - MarketBeat
Keros (KROS) Today: Moves 4.95% Down to $10.55 in the Latest Session; Market Levels: $10.02 and $11.08 Define the Nearby Reference Levels in the Available RecordPut Support - vinanet.vn
Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan
Keros Therapeutics (NASDAQ: KROS) director schedules 551-share sale - Stock Titan
Keros Therapeutics Secures $20 Million Milestone Payment From Takeda - sekbernews.id
Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Wall Street Zen - marketbeat.com
Keros Therapeutics (KROS) Drops 5.25% to $10.1 — Support at $9.59 in FocusEarnings Miss Risk - vinanet.vn
Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity? - Yahoo Finance
Understanding Momentum Shifts in (KROS) - Stock Traders Daily
Keros Therapeutics, Inc. $KROS Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.83, Implies 86% Upside - TradingView
BofA Securities Adjusts Keros Therapeutics Price Target to $17 From $20 - marketscreener.com
KROS Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Investment CostsCapex Guidance - careplusvn.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen - MarketBeat
Renaissance Technologies LLC Sells 138,204 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics, Inc. (KROS) Stock Analysis: Unveiling a 90.92% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - qz.com
FY2026 EPS Estimate for Keros Therapeutics Raised by Analyst - MarketBeat
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus - The Globe and Mail
3.06%
2.55%
자본화:
|
볼륨(24시간):